Tryp Therapeutics

Tryp Therapeutics

Private Company
Public Company
Subsidiary of
Clinical Trials, R&D
Drug Discovery

About

Tryp Therapeutics is a clinical stage drug development company led by a management team with extensive drug development experience that is advancing transformative medicines with existing clinical data and known safety profiles for diseases with no effective first-line treatments. The company is building a diversified portfolio of product candidates targeting neuropsychiatric and oncology indications with high unmet medical needs.

Leadership Team

James Kuo, Chief Executive Officer

  • Chairman of the Board, ImmunoPrecise Antibodies (TSXV:IPA).
  • Former Managing Director of HealthCare Ventures, a $378 Million venture capital fund.
  • Former CEO of BioMicro Systems and Discovery Laboratories.
  • Former Associate Director of Licensing and Development at Pfizer.
  • MD from University of Pennsylvania School of Medicine.
  • MBA from the Wharton School of Business.

William Garner, Executive Chairman

  • Founder of Race Oncology (ASX:RAC)
  • Co-Founder and Director of DelMar Pharmaceuticals (NASDAQ:DMPI)
  • Founder of EGB Ventures, where he was focused on advancing technologies and companies to monetization or assets via licensing, mergers and acquisitions or IPO transactions.

Jay R. Campbell, Chief Business Officer

  • Over 13 years focused on life sciences industry as an investment banker working with private and public companies on strategy, M&A and financing transactions.
  • Successfully worked on 30 M&A and financing transactions representing more than $13.4 billion.

Pipeline / Market Opportunities

TRP-8802 | Prader-Willi Syndrome (PWS)
Serious and complex genetic disorder estimated to affect 8,000-11,000 patients in the U.S. and Europe and market size of ~US$800m according to Jefferies Equity Research.

TRP-8803 | Fibromyalgia
Chronic and debilitating CNS/neurobiological disorder. The fibromyalgia treatment market is estimated to surpass US$3.6B by 2026.

TRP-1001 | Sarcomas
Oncology is the leading therapeutic category and represented 25% of all drug sales in 2018, which equated to ~US$151B in 2018.